Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025

Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide

Read more at globenewswire.com